Novigenix SA, the Swiss precision medicine pioneer, is excited to announce its recent funding milestone of 1,800,000, a strategic investment that will further cement its position at the forefront of transformational healthcare. Specializing in ImmunoTranscriptomic solutions, Novigenix is dedicated to early disease detection, the development of novel therapeutics, and innovative drug target discovery. At the heart of its technological prowess is the proprietary LITOSeek™ platform—a cutting-edge, AI-enabled RNA analytics system designed to meticulously map how the immune system responds from the onset through the progression of diseases. By integrating multi-omics patient data with sophisticated machine learning and artificial intelligence methodologies, the LITOSeek™ platform offers unprecedented actionable insights that empower both researchers and clinicians.
This new influx of capital will fuel the expansion and optimization of Novigenix’s liquid biopsy products and services, specifically enhancing its repertoire of biopharma solutions aimed at clinical development and early detection, notably of cancers such as Colorectal Cancer. The funds will support critical research initiatives, the advancement of clinical pipelines, and the continual refinement of its standardized RNAseq platform and analytic pipelines. With its commitment to developing precision medicine solutions within oncology and immunology, Novigenix is uniquely positioned to deliver innovative biomarkers and therapeutic modalities that address patient heterogeneity in treatment responses. Ultimately, the announced funding will not only accelerate the company’s mission to revolutionize disease management but also reinforce its longstanding dedication to inspiring breakthroughs in patient care and clinical excellence globally.
.png&w=3840&q=75)
